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A simple isocratic reversed-phase high performance liquid chromatographic (RP-HPLC) method 
was developed for determination of oseltamivir active pharmaceutical ingredient (API) in bulk drug and 
pharmaceuticals. The separation was achieved on a Purospher STAR® RP – 18e column with a mobile 
phase consisting of methanol - 0.02 mol l–1 phosphate buffer, pH 5, 50:50 (V/V). Chromatographic results 
demonstrated the specificity of the method for determination of oseltamivir in presence of degradation 
products generated in studies of forced decomposition. The limit of detection (LOD) and limit of quan-
tification (LOQ) for oseltamivir phosphate were 0.0162 μg ml–1 and 0.0491 μg ml–1, respectively. The 
advantages of this method include simple sample treatment, short elution time (less than 6 min) and short 
analysis time (less than 10 min). Furthermore, using methanol instead of acetonitrile in a mobile phase 
composition considerably reduces the laboratory expenses, still retaining adequate sensitivity for routine 
analysis as well as for evaluation of authenticity of Tamiflu® products.
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ЕДНОСТАВЕН ИЗОКРАТЕН РЕВЕРЗНОФАЗЕН HPLC МЕТОД  
ЗА КОНТРОЛА НА КВАЛИТЕТ НА КАПСУЛИТЕ ОСЕЛТАМИВИР 
Овој труд прикажува едноставен метод за определување на активната супстанција оселта-
мивир во суровина за фармацевтска намена и во готов производ со примена на реверзнофазна ви-
соко ефикасна течна хроматографија (RP-HPLC) со изократен начин на елуирање. Раздвојувањето 
беше изведено на колона Purospher STAR® RP – 18e со мобилна фаза составена од метанол -0.02 
mol l–1, фосфатен пуфер, pH 5, 50:50 (V/V). Резултатите ја потврдуваат специфичноста на методот 
за определување на оселтамивир во присуство на разградни продукти добиени со форсирана 
деградација. Границата на детекција (LOD) и границата на квантификација (LOQ) за оселтамивир 
беа 0,0162 μg ml–1 и 0,0491 μg ml–1, соодветно. Предностите на методот се: едноставна подготовка на 
примерокот, кратко време на елуирање (пократко од 6 минути) и кратко време на анализа (пократко 
од 10 минути). Со употреба на метанол наместо ацетонитрил се намалуваат лабораториските 
трошоци, а истовремено се обезбедува задоволителна осетливост за изведување рутинска анализа 
и евалуација на потенцијално фалсификувани примероци на Tamiflu®. 
Клучни зборови: оселтамивир; RP-HPLC; HPLC-DAD; контрола на квалитет; 
     фармацевтски производи.
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1. INTRODUCTION
The 2009 flu pandemic is a global out-
break of a new strain of H1N1 influenza virus, 
often referred to colloquially as “swine flu”. 
The virus, first detected in April 2009, con-
tains a combination of genes from swine, avian 
(bird), and human influenza viruses [1]. People 
in at-risk groups should be treated with antivi-
rals (oseltamivir or zanamivir) as soon as pos-
sible after the first experienced flu symptoms 
[2, 3]. Therapy with a neuraminidase inhibitor 
is especially important for patients with under-
lying risk factors, including pregnancy [4], and 
those with severe or progressive clinical illness 
[5].
Oseltamivir phosphate (Figure 1), man-
ufactured under the trade name Tamiflu® (F. 
Hoffmann–La Roche Ltd) as an ester-type 
prodrug of the neuraminidase inhibitor Ro 64-
0802, has been developed for the treatment 
of A and B strains of the influenza virus [6]. 
Tamiflu® is available as capsules containing 30 
mg, 45 mg, or 75 mg oseltamivir (in the form 
of oseltamivir phosphate) for oral use and as a 
powder for oral suspension, which when con-
stituted with water as directed contains 12 mg 
ml–1 oseltamivir base [6]. It is a widely used 
medication, with global experience exceed-
ing 65 million treatment courses (between the 
drug’s approval in 1999 and June 2010) [7].
Fig. 1. Structure of oseltamivir phosphate
Oseltamivir phosphate (OP) is a white 
crystalline solid with the chemical name 
(3R ,4R ,5S)-4-acetylamino-5-amino-3(1-
ethylpropoxy)-1-cyclohexene-1-carboxylic 
acid, ethyl ester, phosphate (1:1). The chemical 
formula is C
16
H
28
N
2
O
4
 (free base). The molec-
ular weight is 312.4 for oseltamivir free base 
and 410.4 for oseltamivir phosphate salt. 
A literature survey for oseltamivir analy-
sis revealed several methods based on different 
techniques, such as bioassay, capillary elec-
trophoresis, cyclic voltammetry, liquid chro-
ma tographic with fluorescence, mass spectro-
metric and UV detection, among others [8–10]. 
To date, there are a few published reports of 
HPLC methods for measuring oseltamivir [8, 
11]. A sensitive HPLC-mass spectrometry as-
say for oseltamivir carboxylate in plasma and 
urine [12, 13] and an HPLC assay for OP in 
pharmaceutical preparations [14] have been 
described. Joseph-Charles et al. [15] reported 
a HPLC method for the determination of OP 
in dosage forms at 226 nm using a Zorbax 
CN column with a mobile phase consisting 
of methanol and 0.04 M formic acid pH 3.0 
(50:50). Fuke et al. [16] describe the HPLC-
UV detection of oseltamivir carboxylate in 
biological materials, following mixed mode 
cation exchange extraction. Furthermore, Bah-
rami et al. [17] presented a simple RP-HPLC 
method to determine oseltamivir carboxylate 
in human serum using a reverse phase C18 
column with a mobile phase containing 0.05 
M phosphate buffer – acetonitrile, pH 3, 70:30 
(V/V), and a detection wavelength of 215 nm, 
while Narasimhan et al. [18] developed a sta-
bility indicating gradient elution reverse-phase 
HPLC method at the same detection wave-
length with a Kromasil C18 column and a gra-
dient run using a mobile phase consisted of 
triethylamine and acetonitrile. Most recently, 
Aydogmus et al. [19] developed a RP-HPLC 
method for determination of OP in capsules 
and plasma, based on the reaction of the drug 
with 4-chloro-7-nitrobenzofurazan in borate 
buffer solution, while Chabaia et al. [20] used 
monolithic silica HPLC column for determina-
tion of OP in pharmaceutical preparation.
Therefore, our objective was to develop 
a time-saving, cost-effective HPLC method 
with UV detection for oseltamivir determina-
tion, avoiding long steps of sample prepara-
tion and using methanol instead of acetonitrile 
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in a mobile phase composition, which would 
reduce laboratory expenses while still retain-
ing adequate sensitivity for routine analysis 
in a pharmaceutical analytical laboratory, in 
chemical stability studies, as well as for the 
evaluation of potentially counterfeit Tamiflu® 
products.
2. EXPERIMENTAL
2.1. Chemicals and reagents
Commercially available samples, Tami-
flu® capsules for oral use containing 30 mg, 45 
mg, or 75 mg oseltamivir, in the form of osel-
tamivir phosphate, were used in this study. In 
addition to the active ingredient, each capsule 
contains pregelatinized starch, talc, povidone 
K30, croscarmellose sodium, and sodium stear-
yl fumarate. All dosages contain gelatin and ti-
tanium dioxide within their capsule shells. In 
addition, the 30 mg variety contains yellow 
and red iron oxides; the 45 mg variety con-
tains black iron oxide; and the 75 mg variety 
contains yellow, black and red iron oxides. 
Each capsule is printed with blue ink, which 
includes FD&C Blue No. 2 as the colorant [6]. 
Oseltamivir phosphate standard was supplied 
by Roche Diagnostics GmbH, Mannheim. 
Methanol, sodium hydroxide, and hydrochloric 
acid were purchased from Merck (Darmstadt, 
Germany), while triethylamine and hydrogen 
peroxide were purchased from Alkaloid Ltd., 
Skopje. Double-distilled water was used to 
prepare the mobile phase solutions. 
2.2. HPLC instrumentation and conditions
HPLC analyses were performed using an 
Agilent Technologies chromatographic system 
(Hewlett Packard, Avondale, USA) consisting 
of a Model 1200 Series SL pump with a Model 
Agilent series G-1315C DAD detector and a 
Model Agilent 1200 series G-1329B ALS auto 
sampler. Data analyses were done using Agi-
lent Technologies HPLC 1100 software. The 
chromatographic separation was achieved on a 
reversed-phase column Purospher STAR® RP 
– 18e (150 × 4.6 mm i.d., particle size 5 μm), 
with a guard column LiChrospher® 100 RP – 
18 (4 × 4 mm i.d., particle size 5 μm) at 25 °C. 
The mobile phase consisted of a mixture of: 
methanol - 0.02 mol l–1 phosphate buffer (con-
taining 0.02 mol l–1 triethylamine), pH 5, 50:50 
(V/V), filtered through 0.45 μm nylon filter. The 
flow rate was kept at 1.5 ml min–1. Wavelength 
was selected by scanning a standard solution of 
OP over 200–400 nm using Model Lambda 12 
(Perkin Elmer) UV-visible spectrophotometer. 
The wavelength of 215 nm was chosen for de-
tection of oseltamivir phosphate. The injection 
volume was 20 μl.
2.3. Preparation of solutions
A stock solution of OP was prepared by 
dissolving 25 mg of the OP standard  in a sol-
vent mixture (water : methanol, 50:50 (V/V)), 
and diluting with the same solvent up to 25 ml. 
Working standard solution (0.3 mg ml–1) was 
prepared by appropriate dilution of the stock 
standard solution with the same solvent. For 
evaluation of linearity, ten aliquots of the stock 
solution were suitably diluted with the same 
solvent to get standard solutions of OP in con-
centration range of 0.075–0.75 mg ml–1.
Twenty capsules were weighed and the 
net content of each capsule was calculated. 
Capsule powder equivalent to 30 mg OP was 
accurately weighed and transferred to a 100 
ml volumetric flask with addition of about 70 
ml solvent mixture (water : methanol, 50:50 
(V/V)). The mixture was sonicated in an ultra-
sonic bath for 15 min and volume was made up 
to the mark with the same solvent. All solvents 
and solutions for HPLC analysis were filtered 
through a membrane filter (0.45 μm pore size) 
and vacuum degassed before use.
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2.4. Method validation
The proposed method was validated ac-
cording to the guidelines set by the Internation-
al Conference on Harmonization for validation 
of analytical procedures [21, 22]. The param-
eters used to validate the method of analysis 
were: system suitability, specificity, linearity, 
range, accuracy, and precision, limit of detec-
tion (LOD), limit of quantification (LOQ), spe-
cificity and robustness.
2.4.1. System suitability
System suitability testing is an integral 
part of liquid chromatographic method valida-
tion performed to check and ensure on-going 
performance of a chromatographic system. 
The system repeatability was estimated by 6 
repeated injections of working standard solu-
tion at 100% of test concentration (0.3 mg ml–1 
OP). The system suitability parameters were 
calculated according to the recommendation of 
the United States Pharmacopoeia [23, 24]. The 
limits for system suitability parameters sug-
gested in the FDA guideline on “Validation of 
Chromatographic Methods” [25] were used as 
acceptance criteria.
2.4.2. Specificity
Specificity is the ability to assess une-
quivocally the analyte in the presence of com-
ponents which may be expected to be present 
(impurities, degradants, matrix, etc.) [21, 22, 
26]. Specificity of the proposed method was 
demonstrated by spiking the capsule formu-
lation with a known quantity of OP standard, 
then checking for interference with the place-
bo. Additionally, specificity was demonstrated 
by the determination of OP in the presence of 
degradation products generated by forced de-
composition. The stress conditions applied in 
the study were: base hydrolysis (0.05 mol l–1 
NaOH, at room temperature, for 5 hours), acid 
hydrolysis (1 mol l–1 HCl, at 90 ºC, for 30 min-
utes) and oxidative degradation (30 % H
2
O
2
, at 
90 ºC, for 10 minutes). An accurately weighed 
25.0 mg of OP standard was dissolved in 500 
μl of the respective base, acid or hydrogen 
peroxide and kept for specified period of time 
after which the volume was made up to 25.0 
ml with the solvent mixture (water : methanol, 
50:50 (V/V)). Blank solutions were treated in 
the same way.
A thermal degradation was carried out by 
treating OP drug substance in hot-air oven at 
120oC, for 1 hour. 
2.4.3. Linearity and range
For evaluation of linearity the calibration 
curve was obtained at 10 concentration lev-
els of OP standard solutions (0.075–0.75 mg 
ml–1). Additionally, to improve the specificity, 
we evaluated linearity of OP in the presence 
of excipients. We spiked placebo samples with 
one stock active solution at six concentration 
levels (0.15–0.525 mg ml–1). The solutions (20 
μl) were injected in triplicate into a chromato-
graphic system with the previously given chro-
matographic conditions. For evaluation of lin-
earity, the peak area and concentrations were 
subjected to a least square regression analysis 
to calculate calibration equation and determi-
nation coefficient.
2.4.4. Precision
The precision of the analytical procedure 
(intra-assay precision) was investigated by ana-
lyzing six sample solutions obtained by multi-
ple sampling of the same homogeneous sample 
under the prescribed conditions (at 100% of the 
test concentration of OP (0.3 mg ml–1 OP)) on 
the same day, by the same analyst and using the 
same equipment. The intermediate precision of 
the analytical procedure was investigated by 
analyzing sample solutions on three consecutive 
days. The precision of the analytical procedure 
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was expressed as the relative standard deviation 
of a series of measurements. 
2.4.5. Limit of detection and limit of 
quantification
Limit of detection (LOD) and limit of quan-
tification (LOQ) of the proposed method were 
determined by consecutively injecting low con-
centrations of the standard solutions (0.125–1.25 
μg ml–1) using the proposed RP-HPLC method. 
LOD and LOQ were calculated in accordance 
with ICH guidelines [21, 22] as follows: LOD 
= 3.3 SD/S and LOQ = 10 SD/S, where SD is 
the standard deviation of the response (y inter-
cept) and S is the slope of the calibration curve 
obtained.
2.4.6. Accuracy
To study the accuracy of the proposed 
analytical method, recovery tests were con-
ducted using the standard addition method. To 
discover whether excipients interfered with the 
analyte, known amounts of standard were added 
to capsule formulation samples and the resulting 
mixtures were analyzed by the proposed meth-
ods. The percent of recovery was calculated as 
follows:
Recovery (%) = ,
where C
v
 is the total amount of OP measured 
after standard addition, C
u
 the amount of OP in 
the drug formulation, and C
a
 the amount of OP 
added to the formulation.
2.4.7. Method robustness
The capacity of the proposed method to 
remain unaffected by small (deliberate) varia-
tions in parameters was evaluated in order to de-
termine method robustness. Changes were made 
to the following method parameters: flow rate (± 
0,1 ml min–1), organic solvent concentration (± 2 
%), wavelength of detection (± 5 nm), buffer pH 
(± 0.2 pH units), and temperature (± 3 °C).
3. RESULTS AND DISCUSSION
3.1. Method development
A variety of mobile phases were investi-
gated in the development of a HPLC method for 
analysis of OP. These included: methanol – wa-
ter, 50:50 (V/V), acetonitrile – water, 30:70 (V/V), 
methanol – phosphate buffer (pH 3.5–6.5), 50:50 
(V/V), and acetonitrile – phosphate buffer (pH 
3.5–6.5), 30:70 (V/V). The suitability of the mo-
bile phase was decided on a basis of the sensitiv-
ity of the assay, suitability for stability studies, 
ease of preparation, and use of readily available 
cost-effective solvents. Thus, the mobile phase 
consisting of methanol – 0.02 mol l–1, phosphate 
buffer (containing 0.02 mol l–1 triethylamine), 
pH 5, 50:50 (V/V), was found optimal for iso-
cratic determination of oseltamivir in pharma-
ceuticals. The wavelength was selected by scan-
ning the standard solution of OP over 200-400 
nm and the wavelength of 215 nm was chosen 
for detection of oseltamivir phosphate.
Oseltamivir was identified on the basis of 
retention time through comparison with the os-
eltamivir standard. Furthermore, the oseltami-
vir was identified by adding standard to sample 
prior to analysis, which resulted in an increased 
sample peak area that was proportional to the 
added amount. The average retention time of the 
oseltamivir was approximately 5.4 min at a flow 
rate of 1.50 ml min–1. The oseltamivir was deter-
mined in a short time as a sharp single peak. The 
retention time of OP we achieved in our study 
was shorter than those reported previously (5.4 
min versus 6.4 min [14], 9.1 min [17], 10.6 min 
[18], and 18.8 min [16]). About 10 min was re-
quired for each analysis. No interference from 
other degradation products was observed (Fig-
ure 2).
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3.2. Method validation
3.2.1. System suitability
The results of system suitability test were 
found within the acceptable range [25] indicat-
ing that the system was suitable for the intend-
ed analysis (Table 1).
T a b l e  1
Results of system suitability test
Parameter Results Parameter limit
RSD of retention time 0.11 % < 1%
RSD of peak area 0.18 % < 1%
Capacity factor kʹ 3.42 > 2
Tailing factor T 1.3 < 2
Theoretical plate 3444 > 2000
3.2.2. Specificity
In the specificity study, standard solutions 
of OP and the sample solution were injected 
and a single peak was obtained for OP, which 
indicates that there was no interference from 
the excipients used or from the mobile phase. 
Furthermore, forced degradation study was un-
dertaken in order to demonstrate the specificity 
of proposed method. This study also provides 
information about the degradation pathways 
and degradation products that could form dur-
ing storage: OP undergoes degradation in acid-
ic and alkaline hydrolytic conditions whereas 
it is relatively stable when exposed to dry heat 
and oxidation. The result of forced degradation 
studies, with approximate % degradation and 
relative retention time (RRT) of degradation 
products is given in Table 2.
The drug was rapidly degraded under acid-
ic condition using 1 mol l–1 HCl, at 90 ºC, for 30 
Fig. 2. Typical chromatograms obtained from oseltamivir in standard solution (a),
 sample solution (Tamiflu® capsules) (b), mobile phase (c)
T a b l e 2
Results of forced degradation study of oseltamivir
Stress degradation condition Approximate degradation
observed (%)
Relative retention time  
of degradation products
Acid hydrolysis 54.59 0.35, 1.27
Base hydrolysis 5.18 0.32, 0.63
Thermal degradation 3.04 0.32, 0.62, 0.91, 1.32
Oxidative degradation 4.08 0.32, 0.62, 0.89
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minutes. The degradation was associated with a 
rise in a major degradation product at RRT 1.27 
and a minor degradation product at RRT 0.35 
(Figure 3-a).
The extent of hydrolysis under alkaline 
conditions was lower as compared to that in acidic 
conditions, forming minor degradation products 
at RRT 0.32 and 0.63 (Figure 3-b).
The drug was considerably stable to 30 % 
hydrogen peroxide at 90 °C for 10 minutes: only 
minor degradation products at RRT 0.32, 0.62, 
0.91 and 1.32 were formed (Figure 3-c).
No major degradation product was ob-
served after the exposure of the drug substance 
to a temperature of 120 ºC in a hot-air oven for 
1h; minor degradation products at RRT 0.32, 0.62, 
and 0.89 were formed (Figure 3-d).
Fig. 3. Chromatograms of acid degradation (a), basic degradation (b), 
oxidative degradation (c), and thermal degradation of oseltamivir (d)
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HPLC chromatograms of hydrolytic, oxi-
dative and thermal degradation of OP show that 
OP peak is well separated from all the degradation 
products formed during the different stress condi-
tions. Thus specificity study ensures that the de-
veloped analytical method is able to separate and 
quantify OP in presence of different degradation 
products.
3.2.3. Linearity and range
In the present study, linearity was studied in 
the concentration range 0.075–0.75 mg ml–1 OP 
and the following regression equation was found 
by plotting the peak area (y) expressed in mAU 
versus the OP concentration (x) expressed in mg 
ml–1: y = 18525 x – 27.193 (r2 = 0.9999). The 
determination coefficient (r2) demonstrates the 
excellent relationship between the peak area and 
concentration of OP. The calibration curves of os-
eltamivir API and oseltamivir with placebo were 
linear. The regression lines were not significantly 
different from a curve passing through the origin y 
= a x. (P-value of the slope > 0.05). The excipients 
had no influence and there was no matrix effect 
observed (Table 3).
3.2.4. Precision and accuracy
The variation in results obtained within a 
day (RSD = 0.50 %, RSD = 0.79% and RSD = 
0.90%, for Tamiflu® 30 mg capsule, 45 mg cap-
sule, and 75 mg capsule, respectively) and day to 
day variations (RSD = 0.15%) for OP determina-
tion was very low (≤ 2%), which confirmed the 
precision of the method. The statistical data is 
shown in Table 4. 
     T a b l e  3
Characteristics of the linear regression analysis
Parameter Oseltamivir APIa Oseltamivir + excipients
Linearity range (μg ml–1) 0.075–0.75 0.15–0.525
Slope 18525 18728
Intercept –27.193 22.911
Determination coefficient (r2) 0.9999 0.9999
SEb of the intercept 32.542 25.331
SE of the slope 69.928 70.171
P-value of the slope 0.428 0.417
aMean value of 3 determination
bSE – Standard error
      T a b l e  4
Precision of the method 
Precision  Parameter % of declared content (X) RSD (%) Bias (%)
Intra-assay precisiona
30 mg capsule 98.93 0.50 1.07
45 mg capsule 99.75 0.79 0.25
75 mg capsule 96.03 0.90 3.97
Intermediate precisiona,b
Day 1 96.03 0.90 3.97
Day 2 96.14 0.88 3.86
Day 3 96.32 0.91 3.68
X 96.16 0.15 3.84
an = 6
bOnly 75 mg capsules were tested in Intermediate precision
         
213A simple isocratic RP-HPLC method for quality control of oseltamivir capsules
Maced. J. Chem. Chem. Eng. 31 (2), 205–215 (2012) 
The average recovery for the tested amounts 
was 100.32 % ± 0.85 % (n = 6). Mean recovery 
(Table 5) for OP was between 99.13 and 101.34 
% indicating that the developed method was accu-
rate for the determination of OP in pharmaceutical 
formulation.
3.2.5. Limit of detection and limit 
of quantification
The limit of detection (LOD) and limit 
of quantification (LOQ) were 0.0162 μg ml–1 
(corresponding to 0.324 ng OP loaded onto 
column) and 0.0491 μg ml–1 (corresponding 
to 0.982 ng OP loaded onto column), respec-
tively. The proposed HPLC method for OP de-
termination was demonstrated to be sensitive 
for performing the stability indicating assay 
and the assay evaluation for product release 
and stability studies and profiling of Tamiflu® 
capsules.
3.2.6. Robustness
Based on the obtained results from the 
method robustness (RSD < 2%), the proposed 
HPLC analytical method were demonstrated to 
be robust (Table 6). 
T a b l e   5
Accuracy of the method 
Amount added
(mg ml–1)
Amount founda 
(mg ml–1)
Recovery 
(%)
RSD
(%)
Bias
(%)
0.1500 0.1500 100.00 0.59 0
0.2259 0.2289 101.34 0.28 1.34
0.3018 0.3010 99.74 0.16 -0.26
0.3776 0.3818 101.12 0.29 1.12
0.4535 0.4496 99.13 0.15 -0.87
0.5294 0.5324 100.56 0.08 0.56
X 100.32 0.85 0.32
     aMean value of 3 determinations
  T a b l e  6
Robustness of the method
Change in parameter RSD (%) (n = 3)
Flow rate (1.4 ml min–1) 1.01
Flow rate (1.6 ml min–1) 1.47
Organic solvent concentration (48%) 0.49
Organic solvent concentration (52%) 1.69
Detection wavelength (210 nm) 1.54
Detection wavelength (220 nm) 1.32
Buffer pH (4.8) 0.99
Buffer pH (5.2) 1.19
Temperature (22 °C) 0.94
Temperature (28 °C) 0.69
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3.3. Method applications
The validated method was applied for 
the determination of OP in commercially avail-
able Tamiflu® capsules. Figure 2 illustrates two 
typical HPLC chromatograms obtained fol-
lowing the assay of OP reference standard so-
lution and Tamiflu® capsules sample solution, 
respectively. The results of the assay (n = 6) 
undertaken yielded 98.93% (RSD = 0.50%), 
99.75 % (RSD = 0.79%), and 96.03% (RSD = 
0.90%) of label claim for oseltamivir in Tami-
flu® 30 mg capsule, 45 mg capsule, and 75 mg 
capsule, respectively (Table 4). The average 
retention time of oseltamivir was approximate-
ly 5.2 min. The results of the assay indicate 
that the method is specific for the analysis of 
oseltamivir without interference from the ex-
cipients used to formulate and produce these 
capsules.
4. CONCLUSIONS
The proposed HPLC method allows a 
simple, accurate, precise and rapid determina-
tion of oseltamivir API in pharmaceutical dos-
age forms. The important features and advan-
tages of this method include: simple sample 
treatment with sonication of small amounts of 
powder sample at ambient temperature, shorter 
elution time (less than 6 min) and shorter anal-
ysis time than in the previously reported meth-
ods (less than 10 min); good precision (RSD 
less than 2 %) and high recovery (greater than 
99%). Furthermore, avoiding long steps of 
sample preparation and using methanol instead 
of acetonitrile in a mobile phase considerably 
reduces the laboratory expenses, while still 
providing adequate sensitivity for determina-
tion of OP in commercially available Tamiflu® 
capsules. The proposed method could be ap-
plicable for routine analysis in pharmaceuti-
cal analytical laboratory, in chemical stability 
studies as well as for the evaluation of poten-
tially counterfeit Tamiflu® products. 
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